Valuation: Roche Holding AG

Capitalization 280B 363B 306B 266B 494B 32,976B 510B 3,232B 1,291B 15,855B 1,363B 1,335B 55,706B P/E ratio 2026 *
18.2x
P/E ratio 2027 * 17x
Enterprise value 288B 374B 315B 274B 508B 33,909B 525B 3,324B 1,327B 16,303B 1,401B 1,372B 57,281B EV / Sales 2026 *
4.58x
EV / Sales 2027 * 4.32x
Free-Float
87.84%
Yield 2026 *
2.87%
Yield 2027 * 2.94%
1 day+1.50%
1 week-1.05%
Current month+1.74%
1 month+4.18%
3 months+23.59%
6 months+44.86%
Current year+8.71%
1 week 347.8
Extreme 347.8
359.2
1 month 331.2
Extreme 331.2
362.3
Current year 323.2
Extreme 323.2
362.3
1 year 231.9
Extreme 231.9
362.3
3 years 212.9
Extreme 212.9
362.3
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Tech/Sci/R&D Officer 59 10/02/2025
Director TitleAgeSince
Director/Board Member 67 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
+1.62%-1.05%+23.80%+27.79% 366B
-0.40%-7.91%+17.86%+190.95% 918B
+0.92%+2.61%+54.09%+47.82% 574B
-0.91%+1.69%+15.09%+43.62% 393B
+1.74%+3.71%+25.56%+53.07% 301B
+4.62%+7.41%+27.48%+29.73% 300B
+1.19%+0.27%+37.10%+8.31% 291B
-2.62%+0.67%-48.90%-38.29% 223B
-0.34%-0.34%+23.02%+49.78% 196B
+5.72%+6.56%+62.08%+78.10% 183B
Average +1.06%+0.96%+23.72%+49.09% 374.54B
Weighted average by Cap. +0.73%+1.32%+25.04%+72.86%

Financials

2026 *2027 *
Net sales 62.93B 81.58B 68.75B 59.79B 111B 7,404B 115B 726B 290B 3,560B 306B 300B 12,507B 65.2B 84.53B 71.24B 61.95B 115B 7,671B 119B 752B 300B 3,688B 317B 310B 12,959B
Net income 14.61B 18.94B 15.96B 13.88B 25.74B 1,719B 26.61B 168B 67.27B 826B 71.04B 69.57B 2,904B 15.65B 20.29B 17.1B 14.87B 27.57B 1,841B 28.5B 180B 72.05B 885B 76.09B 74.52B 3,110B
Net Debt 7.92B 10.27B 8.66B 7.53B 13.96B 932B 14.43B 91.39B 36.49B 448B 38.53B 37.74B 1,575B 1.07B 1.39B 1.17B 1.02B 1.89B 126B 1.96B 12.39B 4.95B 60.76B 5.22B 5.12B 213B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
12/02/26 356.80 CHF +1.62% 949,527
10/02/26 351.10 CHF -0.76% 786,654
09/02/26 353.80 CHF -0.73% 879,073
06/02/26 356.40 CHF -0.64% 784,298
05/02/26 358.70 CHF -0.53% 1,164,640
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
351.10CHF
Average target price
353.30CHF
Spread / Average Target
+0.63%

Quarterly revenue - Rate of surprise